Innate Pharma will update investors and analysts on its pipeline and strategy
The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II in 2014
Marseille, March 17, 2014
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Company will host a Research and Development Update on April 10, 2014, in New York, from 8am to 1pm.
At this R&D Update, Innate Pharma's management team will review and discuss with attendees Innate Pharma's pipeline and strategy. The Company will present the clinical development plan for IPH2201, a first-in-class NKG2A checkpoint inhibitor, which Phase II in oncology is expected to start in 2014.
Attendance is by invitation only and subject to room capacity.
The R&D Update will be live webcasted and also available after the event at the following link: http://psav.rampard.com/20140410/
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company conducting research and development of innovative immunotherapy drug candidates for cancer and inflammatory diseases.
The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Three product-candidates resulting from the company's research platform are currently being tested in clinical trials, two of which by partners Bristol-Myers Squibb and Novo Nordisk A/S.
Listed on Euronext-Paris, Innate Pharma is based in Marseilles, France, and had 84 employees as at December 31, 2013.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
ISIN code Ticker code | FR0010331421 IPH |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website (www.innate-pharma.com).
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Innate Pharma | ATCG Press |
Laure-Hélène Mercier Director, Investor Relations | Marielle Bricman |
Phone: +33 (0)4 30 30 30 87 | Mob.: +33 (0)6 26 94 18 53 |
investors@innate-pharma.com | mb@atcg-partners.com |